Categories: NewsPharmaceutical

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

WASHINGTON, Sept. 03, 2025 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today the webcast link and change of date for management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference in New York City, to Tuesday, September 9, 3:30 PM Eastern Time.

Dr. Geoff Dow, 60 Degrees Pharma CEO, will present live and management will conduct one-on-one meetings during the conference.

Event: H.C. Wainwright 27th Annual Global Investment Conference
Date: September 9, 2025
Time: 3:30 PM ET
Location: Lotte New York Palace Hotel
Webcast: Register

About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.

The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.

Media Contact:
Sheila A. Burke
SheilaBurke-consultant@60degreespharma.com
(484) 667-6330

Investor Contact:
Patrick Gaynes
patrickgaynes@60degreespharma.com

Staff

Recent Posts

Healthcare Triangle, Inc. Announces 1-for-60 Reverse Stock Split as Part of Nasdaq Compliance Plan

PLEASANTON, Calif., Feb. 6, 2026 /PRNewswire/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"),…

2 hours ago

Rokt Joins American Heart Association’s “Go Red. Shop with Heart” Initiative, Marks Kickoff at NYSE Bell Ringing

NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Rokt, the leading ecommerce technology company using machine learning…

2 hours ago

CIMG Inc. Receives 2025 “High-Quality Listed Company Award” Recognition

HONG KONG, Feb. 6, 2026 /PRNewswire/ -- CIMG Inc. ("CIMG" or the "Company") (Nasdaq: IMG),…

2 hours ago

Airrosti Launches REACH, Bringing a Proven Clinical Breakthrough in Musculoskeletal Care to a National Digital Platform

Validated by Claims Study dated, December,10, 2025, Airrosti providers showed $3.6K+ in savings per member…

2 hours ago

ACG Packaging Materials Joins World Economic Forum’s Global Lighthouse Network as World’s First Pharmaceutical Packaging Company

DAVOS, Switzerland and MUMBAI, India, Feb. 6, 2026 /PRNewswire/ -- ACG Packaging Materials today announced…

2 hours ago

CaseBioscience® Launches CaseCryo® CTG DMSO and CaseStor® HSS at ATW 2026, Advancing Next-Generation Biopreservation for Cell Therapy

Introducing cell therapy–grade cryopreservation and hypothermic storage solutions designed for consistency, quality, and performance across…

2 hours ago